Authors: Jade Parker, Editor
A novel imaging technology, developed by researchers from Imperial College London (UK), could revolutionize how tumor biopsies are graded. The technology, termed ‘digistain’, was recently described in the journal Convergent Science Physical Oncology.
Currently, almost all cancers are diagnosed by excised biopsy specimens whereby the severity of the disease is judged by eye alone through the microscope. It is well known that different practitioners given the same biopsy will only agree on its grade about 70% of the time, resulting in an over treatment problem.